AIM ImmunoTech Inc.

OTCPK:AIMI Stock Report

Market Cap: US$6.4m

AIM ImmunoTech Management

Management criteria checks 2/4

AIM ImmunoTech's CEO is Thomas Equels, appointed in Aug 2015, has a tenure of 9.75 years. total yearly compensation is $1.09M, comprised of 71.9% salary and 28.1% bonuses, including company stock and options. directly owns 5.35% of the company’s shares, worth $341.12K. The average tenure of the management team and the board of directors is 9.2 years and 2.2 years respectively.

Key information

Thomas Equels

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage71.88%
CEO tenure9.8yrs
CEO ownership5.4%
Management average tenure9.2yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Thomas Equels's remuneration changed compared to AIM ImmunoTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$1mUS$783k

-US$17m

Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$1mUS$850k

-US$29m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$1mUS$850k

-US$19m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$2mUS$850k

-US$19m

Sep 30 2021n/an/a

-US$17m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$3mUS$807k

-US$14m

Sep 30 2020n/an/a

-US$12m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$890kUS$703k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$10m

Dec 31 2018US$1mUS$751k

-US$10m

Compensation vs Market: Thomas's total compensation ($USD1.09M) is above average for companies of similar size in the US market ($USD656.30K).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.

CEO

Thomas Equels (71 yo)

9.8yrs

Tenure

US$1,089,725

Compensation

Mr. Thomas K. Equels, Esq. M.S., J.D. serves as Director at BioFlorida Inc since August 2021. He serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.)...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Equels
Executive Vice Chairman9.8yrsUS$1.09m5.35%
$ 341.1k
Robert Dickey
Chief Financial Officer3.1yrsUS$49.55k0%
$ 0
Peter Rodino
COO, Executive Director of Governmental Relations8.6yrsUS$521.35k0.56%
$ 35.4k
Christopher McAleer
Scientific Officer2.4yrsno datano data
Ann Marie Coverly
Director of Administration & Human Resources and Deputy Investor Relations Coordinator12.3yrsno datano data
Ralph Cavalli
Vice President of QC & Manufacturing15.1yrsno datano data

9.2yrs

Average Tenure

69.5yo

Average Age

Experienced Management: AIMI's management team is seasoned and experienced (9.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Equels
Executive Vice Chairman16.5yrsUS$1.09m5.35%
$ 341.1k
David Chemerow
Independent Directorless than a yearno data0.089%
$ 5.7k
Ronald H. Brus
Member of Scientific Advisory Boardno datano datano data
Ted Kellner
Directorless than a yearno data6.93%
$ 441.7k
William Mitchell
Independent Chairman of the Board & Member of Scientific Advisory Board26.8yrsUS$125.00k0.72%
$ 46.0k
Christopher Nicodemus
Member of Scientific Advisory Boardno datano datano data
Nancy Bryan
Independent Director2.2yrsUS$125.00k0.40%
$ 25.7k
W. Burnette
Chairman of Scientific Advisory Boardno datano datano data
Philip Roane
Member of Scientific Advisory Boardno datano datano data

2.2yrs

Average Tenure

72yo

Average Age

Experienced Board: AIMI's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 23:34
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIM ImmunoTech Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Ling WangChardan Capital Markets, LLC
Pravin GondhaleVirtua Research Inc.